Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis

Paul P. Dobesh, Brian J. Trevarrow

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Although venous thromboembolism prophylaxis of acute medically ill patients is commonly employed, a percentage of high-risk patients still have venous thromboembolic events within 30 days of discharge. Research over the last several years has attempted to identify characteristics of these high-risk patients to facilitate provision of extended prophylaxis and venous thromboembolic event reduction; however, extended prophylaxis has been associated with a significant increase in the risk for major bleeding until recently. Betrixaban, a new oral direct Xa inhibitor with once-daily dosing and limited renal elimination, significantly reduces the risk of venous thromboembolism without increasing the risk for major bleeding. Consequently, betrixaban is the only anticoagulant approved by the Food and Drug Administration for preventing venous thromboembolism with extended prophylaxis in acute medically ill patients.

Original languageEnglish (US)
Pages (from-to)307-311
Number of pages5
JournalAmerican Journal of Medicine
Issue number3
StatePublished - Mar 2019


  • Anticoagulation
  • Betrixaban
  • Direct oral anticoagulant
  • Venous thromboembolism prophylaxis

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis'. Together they form a unique fingerprint.

Cite this